Lymphoma News

The FDA granted accelerated approval to glofitamab-gxbm for treatment of certain adults with relapsed or refractory diffuse large B-cell lymphoma.

Editor’s note: This is the first in a series of five stories from ASCO Voices, a session during ASCO Annual Meeting focused on the human side of oncology.

ASCO Chief Medical Officer Julie R. Gralow, MD, FACP, FASCO, urged members of Congress to take action on cancer drug shortages, which she described as the worst she has witnessed during her 30-year career in oncology.

In this video, Matthew Matasar, MD, chief of the division of blood disorders at Rutgers Cancer Institute, discusses mantle cell lymphoma research presented at ASCO Annual Meeting.

CHICAGO — Healio | HemOnc Today gathered the best, brightest and boldest in oncology for its second annual Disruptive Innovators Awards.

The FDA announced several regulatory actions the past few weeks.

CHICAGO — Lisocabtagene maraleucel significantly improved complete remission rates among adults with relapsed or refractory chronic lymphocytic leukemia, results from the pivotal phase 2 TRANSCEND CLL 004 trial showed.

INDIANAPOLIS — Compared with siblings, survivors of childhood cancer have an increased risk for sleep concerns up to 30 years after diagnosis, according to a report from the Childhood Cancer Survivor Study.

CHICAGO — Radiation therapy can be safely omitted for patients with primary mediastinal B-cell lymphoma who demonstrate a complete metabolic response after chemoimmunotherapy, according to data presented at ASCO Annual Meeting.

CHICAGO — A split-dose approach to the standard R-CHOP chemotherapy regimen resulted in a 71% complete response rate among older adults with newly diagnosed diffuse large B-cell lymphoma, results from a phase 2 study showed.